Elan Corporation News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.11.17	/R E P E A T -- Preserving Antibiotic Effectiveness: It's a question of life or death/ (PR Newswire)
18.12.13	Perrigo Completes Elan Acquisition (RTTNews)
18.12.13	Perrigo Company plc Completes Acquisition of Elan Corporation, plc (Businesswire)
13.12.13	Irish High Court Oks Perrigo's Proposed Acquisition Of Elan - Quick Facts (RTTNews)
13.12.13	Perrigo Company and Elan Corporation Plc Receive Irish High Court Approval for Perrigo’s Proposed Acquisition of Elan (Businesswire)
18.11.13	Elan Says Shareholders Approve Its Acquisition By Perrigo Co. - Quick Facts (RTTNews)
18.11.13	Elan Announces Shareholder Approval of its Acquisition by Perrigo Company (Businesswire)
24.10.13	Elan Reports Third Quarter 2013 Financial Results (Businesswire)
16.10.13	Awareness Programs, Restructuring Efforts, Conference Calls, Marketing Authorization Withdrawal and Clinical Trial Commencement - Research Report on Lilly, Teva, Elan, Zoetis, and Boston Scientific (PR Newswire)
15.10.13	Under AAAResearchReports.com Microscope: Amarin Corp. PLC, Elan Corp. PLC, Seattle Genetics Inc., and Cubist Pharma Inc. (PR Newswire)
10.10.13	Elan Announces Webcast of Third Quarter 2013 Financial Results (Businesswire)
10.10.13	Le gouvernement du Canada appuie la mémoire et l'éducation au sujet de l'Holocauste (PR Newswire)
10.10.13	Perrigo Company Announces Date Of Special Shareholder Meeting In Connection With Acquisition Of Elan Corporation, plc (PR Newswire)
04.10.13	Events, Appointments, Approvals, Recommendations, and Agreements - Research Report on Elan, Alkermes, Hospira, pSivida, and Kindred (PR Newswire)
30.09.13	Elan Announces Dates of Shareholder Meetings in Connection with Scheme of Arrangement (Businesswire)
16.09.13	Pre-Market Analysis: Amarin Corp. PLC, Elan Corp. PLC, Cubist Pharmaceuticals Inc., and Seattle Genetics Inc. (PR Newswire)
11.09.13	Acquisitions, Regulatory Filings, New Community Resource Centers and Successful Clinical Trials- Research Report on Baxter, Endo, HCA, Elan, and Theravance (PR Newswire)
04.09.13	Transition: First Patient Dosed In Phase 2a Study Of ELND005 In Down Syndrome (RTTNews)
03.09.13	Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome (Businesswire)
28.08.13	Perrigo Files Registration Statement On Form S-4 In Connection With Proposed Acquisition Of Elan (PR Newswire)
28.08.13	Perrigo Files Registration Statement on Form S-4 in Connection with Proposed Acquisition of Elan (Businesswire)
08.08.13	Today's Research: Elan Corp. PLC, Amarin Corp. PLC, Seattle Genetics Inc., and Cubist Pharmaceuticals Inc. (PR Newswire)
29.07.13	Pre-market Movers For July 29 (SKA, ELN, OMC, PRGO, WYNN, CHTP) (RTTNews)
29.07.13	New License Agreements and Financial Results Release - Research Report on Elan, Waters, InterMune, Spectranetics, and Ligand (PR Newswire)
29.07.13	Perrigo Agrees To Buy Elan In $8.6 Bln Cash And Stock Deal (RTTNews)
29.07.13	Perrigo To Buy Elan In $8.6 Bln Transaction - Quick Facts (RTTNews)
24.07.13	Elan Corp Reports Profit In Q2 - Quick Facts (RTTNews)
24.07.13	Elan Reports Second Quarter and First Half 2013 Financial Results (Businesswire)
23.07.13	FDA Designations to Development Programs and Quarterly Financial Results Schedules - Research Report on Valeant, Elan, Alkermes, Teva and Gilead (PR Newswire)
17.07.13	Elan: FDA Grants Fast Track Designation To ELND005 For Treatment Of NPS In AD (RTTNews)
17.07.13	FDA Grant Fast Track Designation to ELND005 for the Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease (Businesswire)
02.04.13	Elan Announces Closing of TYSABRI® Collaboration Transaction with Biogen Idec (Businesswire)
21.12.12	Elan Announces Completion of Demerger of Prothena Corporation plc (Businesswire)
19.12.12	Elan Announces Availability of Information Statement in Respect of Prothena Corporation plc (Businesswire)
14.12.12	Elan Announces Expected Timetable in Respect of Implementation of Proposed Demerger (Businesswire)
12.12.12	Resolution to Approve the Prothena Business Demerger Passed at Elan EGM (Businesswire)
05.12.12	Elan Announces Record Date in Respect of Proposed Demerger (Businesswire)
27.11.12	Elan Announces Enrollment of First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer’s Disease (Businesswire)
13.11.12	Elan Announces Publication of EGM Circular in Respect of Proposed Demerger (Businesswire)
24.10.12	Elan Reports Third Quarter 2012 Financial Results (Businesswire)
23.10.12	Elan Announces Expiration of Cash Tender Offer and Consent Solicitation for 8.75% Senior Notes due 2016 (Businesswire)
11.10.12	TYSABRI® (natalizumab) DATA AT ECTRIMS REAFFIRM POSITIVE EFFECTS OF TREATMENT FOR PEOPLE WITH RELAPSING FORMS OF MS (Businesswire)
10.10.12	Elan Announces Webcast of Third Quarter 2012 Financial Results (Businesswire)
08.10.12	Elan Announces Results Through Consent Payment Deadline of Cash Tender Offer and Consent Solicitation for 8.75% Senior Notes Due 2016 (Businesswire)
01.10.12	Elan Announces Redemption of Its Senior Notes Due 2016 (Businesswire)
25.09.12	Elan Announces Pricing of $600 Million 2019 Senior Notes (Businesswire)
25.09.12	Elan Announces Intent to Offer US$500 Million in Aggregate Principal Amount of Senior Notes Due 2019 (Businesswire)
24.09.12	Elan Announces Commencement of Tender Offer and Consent Solicitation (Businesswire)
20.09.12	Elan Announces the Appointment of Hans Peter Hasler as Chief Operating Officer (Businesswire)
29.08.12	Elan Announces Dosing of First Patient in Phase 2 Trial of ELND005 (Scyllo-inositol) in Bipolar Disorder (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Kuehne+Nagel Int	209.20	2.65 %	K V
CieFinRichemont	178.70	1.59 %	K V
ABB	50.72	1.28 %	K V
Nestle	78.30	1.22 %	K V
Novartis	97.87	0.96 %	K V
Sonova Hldg	305.70	0.26 %	K V
Part Grp Hldg	1’409.50	0.21 %	K V
Swisscom	527.00	0.19 %	K V
Swiss Re	142.25	0.18 %	K V
Roche Hldg G	288.50	-0.72 %	K V

Nachrichten zu Elan Corporation PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten